

Name of listed company: Chugai Pharmaceutical Co., Ltd.  
Code number: 4519 (1<sup>st</sup> Section of Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo  
Chairman & CEO: Osamu Nagayama  
Inquiries to: Masahiko Uchida, General Manager,  
Corporate Communications Dept.  
Tel: +81-(0)3-3273-0881

## Correction to Supplementary Materials for Consolidated Financial Results

Chugai Pharmaceutical Co., Ltd. announced today a correction of “Supplementary Materials for Consolidated Financial Results for the 1st Quarter of Fiscal Year 2013. 12 (IFRS)”, “Supplementary Materials for Consolidated Financial Results for the 2nd Quarter of Fiscal Year 2013. 12 (IFRS)”, and “Supplementary Materials for Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2013. 12 (IFRS)” as described below.

### Correction:

- (1) Supplementary Materials for Consolidated Financial Results for the 1st/2nd/3rd Quarter of Fiscal Year 2013. 12 (IFRS)

Page 4 Financial highlights (Core results QTR) Operating expenses / % of Revenues

\*The same table is used in these three materials, and corrections are in common.

- (2) Supplementary Materials for Consolidated Financial Results for the 1st/2nd/3rd Quarter of Fiscal Year 2013. 12 (IFRS)

Page 10 Performance indicators Dividends on equity (DOE)

\*The same table is used in these three materials, and corrections are in common.

- (3) Supplementary Materials for Consolidated Financial Results for the 2nd Quarter of Fiscal Year 2013. 12 (IFRS)

Supplementary Materials for Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2013. 12 (IFRS)

Page 10 Performance indicators Core return on net operating assets (Core RONO)

- (4) Supplementary Materials for Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2013. 12 (IFRS)

Page 6 Statements of revenues (YTD) Oncology - Other products

- (5) Supplementary Materials for Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2013. 12 (IFRS)

Page 7 Statements of revenues (QTR) Oncology - Other products

(1) Page 4 Financial highlights (Core results QTR)

(Before correction)

(Billions of Yen)	
	Actual
	FY2012
	10-12
	QTR
Operating expenses	(40.3)
(% of Revenues)	36.3

(After correction)

(Billions of Yen)	
	Actual
	FY2012
	10-12
	QTR
Operating expenses	(40.2)
(% of Revenues)	36.2

(2) Page 10 Performance indicators

(Before correction)

	Units	Actual			
		FY2012			
		1-3	1-6	1-9	1-12
		As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31
Dividends on equity (DOE)	%	4.1			

(After correction)

	Units	Actual			
		FY2012			
		1-3	1-6	1-9	1-12
		As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31
Dividends on equity (DOE)	%	4.2			

(3) Page 10 Performance indicators

2nd Quarter of Fiscal Year 2013. 12 (IFRS)

(Before correction)

	Units	Actual	
		FY2013	
		1-6	1-9
		As of Jun. 30	As of Sep. 30
Core return on net operating assets (Core RONO)	%	<u>7.9</u>	

(After correction)

	Units	Actual	
		FY2013	
		1-6	1-9
		As of Jun. 30	As of Sep. 30
Core return on net operating assets (Core RONO)	%	<u>8.1</u>	

3rd Quarter of Fiscal Year 2013. 12 (IFRS)

(Before correction)

	Units	Actual	
		FY2013	
		1-6	1-9
		As of Jun. 30	As of Sep. 30
Core return on net operating assets (Core RONO)	%	<u>7.9</u>	<u>12.4</u>

(After correction)

	Units	Actual	
		FY2013	
		1-6	1-9
		As of Jun. 30	As of Sep. 30
Core return on net operating assets (Core RONO)	%	<u>8.1</u>	<u>12.7</u>

## (4) Page 6 Statements of revenues (YTD)

(Before correction)

(Billions of Yen)

	Actual	
	FY2013	
	1-9	Change (%)
	YTD	
Sales	288.8	+7.5
Excl. Tamiflu	279.7	+7.4
Domestic	234.4	+2.0
Oncology	121.5	+9.2
Other products	<u>6.0</u>	<u>+1.7</u>

(After correction)

(Billions of Yen)

	Actual	
	FY2013	
	1-9	Change (%)
	YTD	
Sales	288.8	+7.5
Excl. Tamiflu	279.7	+7.4
Domestic	234.4	+2.0
Oncology	121.5	+9.2
Other products	<u>5.5</u>	<u>(6.8)</u>

## (5) Page 7 Statements of revenues (QTR)

(Before correction)

(Billions of Yen)

	Actual	
	FY2013	
	7-9	Change (%)
	QTR	
Sales	99.9	+12.9
Excl. Tamiflu	99.9	+13.0
Domestic	82.4	+3.8
Oncology	42.8	+10.3
Other products	<u>2.3</u>	<u>+15.0</u>

(After correction)

(Billions of Yen)

	Actual	
	FY2013	
	7-9	Change (%)
	QTR	
Sales	99.9	+12.9
Excl. Tamiflu	99.9	+13.0
Domestic	82.4	+3.8
Oncology	42.8	+10.3
Other products	<u>1.8</u>	<u>(10.0)</u>